TABLE 1.
TCC and libraryb | [3H]thymidine incorporation (mean cpm) with:
|
||
---|---|---|---|
Stimulus | Controlc
|
||
Medium | HSV-2 | ||
4.2E1 | 286 | 21,591 | |
pUEX1–BamHI w-SmaI | 10,105 | ||
pUEX2–BamHI w-SmaI | 4,150 | ||
pUEX3–BamHI w-SmaI | 1,903 | ||
2.3 | 102 | 11,014 | |
pUEX1–BamHI w-SmaI | 418 | ||
pUEX2–BamHI w-SmaI | 785 | ||
pUEX3–BamHI w-SmaI | 2,279 | ||
ESL4.9 | 146 | 66,013 | |
pUEX1–HG52–SmaI-AluI | −52 | ||
pUEX2–HG52–SmaI-AluI | −25 | ||
pUEX3–HG52–SmaI-AluI | 16,235 | ||
ESL2.20 | 123 | 13,359 | |
pUEX1–HG52–SmaI-AluI | 1 | ||
pUEX2–HG52–SmaI-AluI | 768 | ||
pUEX3–HG52–SmaI-AluI | 5,427 |
Proliferation is expressed as [3H]thymidine incorporation. Autologous EBV-LCL (clones 4.2E1 and 2.3) or PBMC were used as APC, and library-derived fusion protein antigens were diluted 1:300.
Library designations consist of an expression vector, the HSV-2 restriction fragment or strain of full-length viral DNA, and the restriction enzyme(s) used to digest viral DNA.
Controls consisted of 105 autologous irradiated (3,300 rads) PBMC and either mock-infected cell lysate or UV-treated HSV-2 antigen.